| Company Information |
| Address: |
Belvedere House Basing View Basingstoke Hampshire RG21 4HG
|
Index: |
FTSE 250 FTSE 350 FTSE 350 Lower Yield FTSE All Share FTSE TechMark Focus FTSE TechMark All Share FTSE TechMark Mediscience
|
| Tel: |
+44(0)1256 347100
|
Sector: |
Pharmaceuticals
|
| Fax: |
+44 (0)1256 477385 |
|
|
| E-Mail: |
|
Epic: |
GNS |
| Secretary: |
Ian Farrelly |
|
|
| Registrar: |
Equiniti Ltd
|
Updated: |
15/11/2012 |
Company Overview
Genus applies biotechnology to advance the science of animal breeding. As the world leader in improving porcine and bovine stock, they play a crucial role in the global agricultural economy. The progeny of their robust and highly productive pigs and cattle enable Genus customers - farmers and food producers in 70 countries to meet growing demand for meat and milk despite tightening constraints on resources available for food production.
Company Strategy
Genus has developed a robust strategy to capture the very significant growth opportunities in the animal genetics market, particularly in the BRIC countries. To achieve this, Genus will increasingly focus on customer needs and adopt a stronger market place orientation. The detailed strategies to support this call for continuing commitment to R & D and focus on key markets and segments while strengthening key competencies.
| |
|
|
|
| Dividend History |
|
| Type |
Payment Date |
Dividend |
|
| Final |
8/11/2012 |
10.1 p |
|
| Interim |
30/03/2012 |
4.5 p |
|
| Final |
25/11/2011 |
13.3 p |
|
| Final |
7/01/2011 |
12.1 p |
|
| Final |
8/01/2010 |
11 p |
|
| Final |
9/01/2009 |
10 p |
|
| Final |
4/01/2008 |
9.1 p |
|
| Final |
1/12/2006 |
8.25 p |
|
| Final |
30/08/2005 |
7.5 p |
|
| Final |
18/08/2004 |
6.5 p |
|
| Final |
27/08/2003 |
5.5 p |
|
| Final |
9/09/2002 |
4.75 p |
|
| Final |
7/09/2001 |
4.5 p |
|
| Final |
1/09/2000 |
4.5 p |
|
|
|
|